558 related articles for article (PubMed ID: 30257451)
1. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
[TBL] [Abstract][Full Text] [Related]
2. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
[TBL] [Abstract][Full Text] [Related]
3. IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J
Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.
Cheng W; Ren X; Zhang C; Han S; Wu A
J Neurooncol; 2017 Apr; 132(2):207-218. PubMed ID: 28091987
[TBL] [Abstract][Full Text] [Related]
5. Large-Scale Drug Screening in Patient-Derived IDH
Dao Trong P; Jungwirth G; Yu T; Pusch S; Unterberg A; Herold-Mende C; Warta R
Cells; 2020 Jun; 9(6):. PubMed ID: 32503220
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
7. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Lvu W; Fei X; Chen C; Zhang B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
10. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
11. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
12. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
13. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
15. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
[TBL] [Abstract][Full Text] [Related]
16. IDH1
Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Role of EYA4 in Lower Grade Glioma with IDH1 Mutation and 1p19q Co-Deletion.
Zhu J; Hu LB; Zhao YP; Zhang YQ
World Neurosurg; 2021 May; 149():e1174-e1179. PubMed ID: 33631386
[TBL] [Abstract][Full Text] [Related]
18. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
19. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
[TBL] [Abstract][Full Text] [Related]
20. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]